Poland· PL-100341809
Egzysta
A pregabalin product containing pregabalinum, registered in Poland by Adamed Pharma S.A.. The same ATC class is registered in 3 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Pregabalin is registered in 3 of 19 countries.
Countries holding a registration under ATC N03AX16 (pregabalin), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 2 of them publish a price we can compare per daily dose
Pregabalin · ATC N03AX16
3 / 19 countries
- Belgiumprice
- Ireland
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Pregabalinum
- Manufacturer
- Adamed Pharma S.A.
- Country
- Poland (PL)
- ATC code
- N03AX16
- ATC class
- Pregabalin
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 4
1 priced- gtin0590041101444170 szt.PLN 121.23
- gtin05906414001129
- gtin05906414001136
- gtin05906414001143
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
282 interactions on record for pregabalin.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pregabalin · interactions on record
282 records
- 4 severe
- 60 moderate
- 180 info
Most severe, free to view
- MorphineN02AA01severe
- MorphinN07BC09severe
- HydrocodoneR05DA03severe
- CodeineR05DA04severe
38 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under N03AX16
Pregabalin, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f6919de2-2621-4038-8857-cb351a2718d2 GET /v1/drugs/f6919de2-2621-4038-8857-cb351a2718d2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Kapsułki twarde",
"source": "urpl",
"strength": "150 mg",
"packaging": "05906414001129 ¦ Rp ¦ 110545\n14 kaps.\n05906414001136 ¦ Rp ¦ 110546\n28 kaps.\n05906414001143 ¦ Rp ¦ 110547\n56 kaps.\n05900411014441 ¦ Rp ¦ 166764\n70 kaps.",
"substance": "Pregabalinum 150 mg",
"common_name": "Pregabalinum",
"pl_product_id": "100341809",
"pozwolenie_nr": "22618",
"auth_procedure": "DCP",
"authorisation_validity": "Bezterminowe"
}See everything about pregabalin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.